Lucas Montarce

All these public prices, we have been very disciplined on our pricing strategy.

You can look at the results quarter on quarter that we maintain that discipline throughout 2025.

And my commitment is to maintain that price discipline getting into 2026 as well.

That's a great point.

Of course, again, not only Tercepetide, again, Cepbound, but also Orfoglipron will be available in the Medicare segment once that access is provided.

So both molecules will have access to Medicare patients and the patients will pay, actually $50 will be the copay that the patients will be paying for both medicines.

So great opportunity to drive access.

I mentioned 40 million patients.

As always, penetrations will build over time.

So starting off July, hopefully we will see that penetration growing over time.

So that will build not only in 2026, but also getting into 2027 as well.

Yeah, it's great news, by the way.

I'm glad that you brought it up, because you asked me about the QuickPen approval.

And again, it has been three weeks, and now we have the QuickPen approval, and we are planning to bring it to the market within the next 30 days.

So that will bring another option.

Of course, again, we are discussing about the channel segments.

You mentioned Medicare being one of them.

But also, we will bring it in direct to patients.

So that we will have more broad access is another opportunity, another option for patients that will have

the opportunity to get to the QuickPen device.